Home › Lupus › Missouri › Kansas City
Lupus clinical trials in Kansas City, MO
3 studies for Lupus are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 5 mi away
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RecruitingPhase 3
- Sl0044 50682, Kansas City
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
RecruitingPhase 3
- Research Site, Kansas City
About Lupus
Lupus is an autoimmune disease that causes your immune system to attack your healthy tissues and cells. This can cause damage to many parts of your body.
More about Lupus on MedlinePlus
Lupus trials in other cities
- New York City, NY18 studies
- Houston, TX13 studies
- Durham, NC12 studies
- Miami, FL11 studies
- Washington, DC10 studies
- Tampa, FL9 studies
- Philadelphia, PA9 studies
- Clearwater, FL8 studies
- Santa Monica, CA8 studies
- Oklahoma City, OK8 studies
- Los Angeles, CA8 studies
- Chicago, IL8 studies
Other studies in Kansas City
- Breast Cancer34 studies
- Non-Small Cell Lung Cancer31 studies
- Heart Failure25 studies
- Cancer (all types)21 studies
- Lung Cancer19 studies
- Colorectal Cancer16 studies
- Metastatic Cancer15 studies
- Acute Myeloid Leukemia15 studies
- Prostate Cancer14 studies
- Ovarian Cancer11 studies
- Obesity11 studies
- Type 2 Diabetes11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.